An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus

NCT ID: NCT01001611

Last Updated: 2013-07-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 173 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-10-31
• Study Completion Date: 2012-01-31

Brief Summary

The purpose of this study is to evaluate and confirm hypoglycemic efficacy and safety of CKD-501 as mono therapy in patients with type 2 diabetes treated once daily for 24 weeks in comparison to placebo.

Detailed Description

Diabetes Mellitus is classified into type 1 diabetes and type 2 diabetes mellitus according to the causes of diabetes onset and the treatment of symptoms.

In type 2 diabetes, the combination of insulin resistance and insulin deficiency is working. Diabetes mellitus causing many complications and hospitalization is one of chronic metabolic disorder and diabetes mortality rate has been gradually increasing percentage.

CKD-501 is highly selective peroxisome proliferator-activated receptor-gamma agonist that decreases insulin resistance in the periphery and liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. In vivo, It demonstrates that CKD-501 improves even more glycemic and lipid control in comparison to rosiglitazone and pioglitazone.

The aim of this phase 3 study was to evaluate the efficacy and safety of CKD-501 once daily for 24 weeks as a monotherapy in type 2 diabetes mellitus. Furthermore, the extension study for additional 28 weeks is designed to confirm long term safety of CKD-501 as an oral hypoglycemic agent.

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

CKD-501 0.5mg

Group Type: EXPERIMENTAL

CKD-501 0.5mg

Intervention Type: DRUG

0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks

Interventions

CKD-501 0.5mg

0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)

Intervention Type: DRUG

Placebo

Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks

Intervention Type: DRUG

Other Intervention Names

Lobeglitazone

Eligibility Criteria

Inclusion Criteria

• Type Ⅱ diabetes mellitus
• Between 18 years and 80 years old
• The patient who has been taking oral hypoglycemic agent since 3 months with HbA1c 6.5 to 9% at screening test or who is drug naive or stopped taking oral hypoglycemic agent more then 3 months with HbA1c 7 to 10% at screening test
• BMI between 21kg/㎡ and 40kg/㎡
• Diagnosis of type Ⅱ diabetes before 3 months
• C-peptide level is over 1.0 ng/ml
• Condition for female having contraception methods, surgical sterilization or menopause
• Condition for male agreeing to use of recommendatory and appropriate contraception method
• Agreement with written informed consent

Exclusion Criteria

• Type I diabetes, gestational diabetes or secondary diabetes
• Treatment with insulin or thiazolidinediones within 60 days
• Fasting Plasma Glucose level is over 250 mg/dl
• Triglyceride level is 500 mg/dl and over
• Uncontrollable hypertension(Although treat with antihypertension agent, systolic blood pressure greater than 140 mmHg and diastolic blood pressure greater than 90 mmHg)
• History of myocardial infarction, heart failure, cerebral infarction, hematencephalon or unstable angina within 6 months
• Severe hepatic dysfunction: AST, ALT, Total bilirubin, ALP level over or equal to 2.5 times as high as upper normal limit(UNL)
• Severe renal dysfunction: Renal failure or serum creatinine greater than 30% normal limit
• Anemia for any reason
• Needs treatment for acute disease, uncontrolled other diseae or diabetic complications
• Abnormality of thyroid function(out of normal TSH range )
• History of proliferative diabetic retinopathy
• In treatment concomitant drug having severe risk drug interaction with investigational drug
• History of cancer within 5 years
• History of drug abuse or alcoholism
• Hepatitis B Antigen(HBsAg) test is positive
• Treatment systemic or inhalant corticosteroids within 1 month prior to Screening
• Patient who have experience such as hypersensitivity reaction, serious adverse event or no effect by treatment with glitazones
• Fertile women who not practice contraception with appropriate methods
• Pregnant women or nursing mothers
• Has a contraindication to treatment investigational drug from the medical and psychogenic side
• An impossible one who participates in clinical trial by legal or investigator's decision
• Participated in other trial within 4 weeks
• Participating in other trial at present

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chong Kun Dang Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dongseop Choi

Role: STUDY_CHAIR

The Korea University Anam Hospital

Locations

The Inje University Busan-Paik Hospital

Busan, , South Korea

Soon Chun Hyang University Cheonan Hospital

Cheonan, , South Korea

The Hanyang University Medical Center

Gyeonggi-do, , South Korea

Wonju Severance Christian Hospital

Kangwon-Do, , South Korea

The Hallym University Medical Center

Seoul, , South Korea

The Inje University Sanggye-Paik Hospital

Seoul, , South Korea

The Korea University Anam Hospital

Seoul, , South Korea

The Kyung Hee University Medical Center

Seoul, , South Korea

The Seoul National University Bundang Hospital

Seoul, , South Korea

Countries

South Korea

References

Kim SG, Kim DM, Woo JT, Jang HC, Chung CH, Ko KS, Park JH, Park YS, Kim SJ, Choi DS. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLoS One. 2014 Apr 15;9(4):e92843. doi: 10.1371/journal.pone.0092843. eCollection 2014.

Reference Type: DERIVED

PMID: 24736628 (View on PubMed)

Other Identifiers

19DM09B

Identifier Type: -

Identifier Source: secondary_id

CKD-19DM09B

Identifier Type: -

Identifier Source: org_study_id